Jing Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jing Yang has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Yuan Zhou
State Key Laboratory of Experimental Hematology, Institute of Hematology and Hospital of Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China
2 shared publications Baiyun Dai
Key Laboratory of Aging and Cancer Biology of Zhejiang Province, Hangzhou, China
1 shared publicationChao Chen
State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
1 shared publication- Chuan Wang
Affiliated Hospital of Hebei University, Clinical Medical College, Hebei University, Baoding, China (J.S., Yiyi Zhang, C.W.).
1 shared publication - Chuan Wang
Department of Pharmacology, Hebei Medical University, Shijiazhuang, China
1 shared publication - Cong Wang
The Key Laboratory of New Drug Pharmacology and Toxicology Hebei Medical 11 University 050017 Shijiazhuang China
1 shared publication
Latest Publications
- Open Access
- 28 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (19) , 8675
Effects and Therapeutic Strategies of Intra-Hepatic Cellular Senescence and Regeneration
The liver constitutes a vital organ characterized by remarkable regenerative capacity, wherein intra-hepatic cellular senescence and regeneration exert pivotal regulatory functions in maintaining hepatic homeostasis and in developing therapeutic interventions for liver diseases. Intra-hepatic cellular aging is typically characterized by diminished proliferative capacity, genomic instability, mitochondrial dysfunction, and exacerbated inflammatory responses, all of which contribute to hepatic functional impairment and the pathogenesis of associated diseases. Liver regeneration depends upon the proliferation and differentiation of hepatocytes—processes stringently regulated by diverse signaling pathways and microenvironmental factors. Notably, the relationship between hepatocyte aging and regeneration embodies a fundamental paradox: whereas acute, transient senescence may facilitate tissue repair through the senescence-associated secretory phenotype (SASP), chronic accumulation of senescent cells disrupts the hepatic microenvironment and suppresses regenerative capacity. This duality necessitates nuanced therapeutic strategies capable of distinguishing between beneficial and detrimental senescent cell populations. Interventions targeting cellular senescence, encompassing small-molecule anti-aging compounds, gene therapy, and stem-cell-based approaches, may represent promising therapeutic modalities for future liver disease management. This review reviews the molecular mechanisms underlying hepatocyte aging and regeneration, critically examines the contradictory roles of senescence in hepatic repair, and explores strategies that selectively target pathological senescence to promote liver regeneration. These insights may provide novel perspectives for the prevention and treatment of liver diseases.
- 28 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (19) , 8675
Open AccessEffects and Therapeutic Strategies of Intra-Hepatic Cellular Senescence and Regeneration
The liver constitutes a vital organ characterized by remarkable regenerative capacity, wherein intra-hepatic cellular senescence and regeneration exert pivotal regulatory functions in maintaining hepatic homeostasis and in developing therapeutic interventions for liver diseases. Intra-hepatic cellular aging is typically characterized by diminished proliferative capacity, genomic instability, mitochondrial dysfunction, and exacerbated inflammatory responses, all of which contribute to hepatic functional impairment and the pathogenesis of associated diseases. Liver regeneration depends upon the proliferation and differentiation of hepatocytes—processes stringently regulated by diverse signaling pathways and microenvironmental factors. Notably, the relationship between hepatocyte aging and regeneration embodies a fundamental paradox: whereas acute, transient senescence may facilitate tissue repair through the senescence-associated secretory phenotype (SASP), chronic accumulation of senescent cells disrupts the hepatic microenvironment and suppresses regenerative capacity. This duality necessitates nuanced therapeutic strategies capable of distinguishing between beneficial and detrimental senescent cell populations. Interventions targeting cellular senescence, encompassing small-molecule anti-aging compounds, gene therapy, and stem-cell-based approaches, may represent promising therapeutic modalities for future liver disease management. This review reviews the molecular mechanisms underlying hepatocyte aging and regeneration, critically examines the contradictory roles of senescence in hepatic repair, and explores strategies that selectively target pathological senescence to promote liver regeneration. These insights may provide novel perspectives for the prevention and treatment of liver diseases.
- Open Access
- 1 February 2026
- Published by China Science Publishing & Media Ltd. in Acta Biochimica et Biophysica Sinica
- Vol. 58 (7) , 1509-1518
Fibroblast growth factor 13 deficiency attenuates doxorubicin-induced cardiotoxicity by regulating Parkin-mediated myocardial injury
The clinical use of doxorubicin (DOX) as a chemotherapeutic agent is limited by its cardiotoxic effects. Fibroblast growth factor (FGF) isoform 13, a distinct type of FGF, has been increasingly recognized as an important regulator of cardiovascular disease. However, its role in doxorubicin-induced cardiotoxicity remains unknown. Therefore, the objective of this study is to investigate the role and mechanism of FGF13 in doxorubicin-induced cardiac injury. C57BL/6 mice are used to establish Dox-induced cardiotoxicity models. The results reveal that mouse weight, cardiomyocyte cross-sectional area, ejection fraction and fractional shortening are decreased in the DOX group. In contrast, Fgf13 deficiency mitigate doxorubicin-mediated cardiotoxicity, as indicated by increased mouse weight, cardiomyocyte cross-sectional area, ejection fraction and fractional shortening. Mechanistically, the protein expressions of bax and cleaved caspase 3 are elevated in the DOX-treated group, along with decreased JC-1 fluorescence intensity and bcl-2 expression, whereas Fgf13 knockout prevented these alterations. In addition, Parkin, but not p53, interact with FGF13 and is upregulated in response to Fgf13 deficiency in a mouse model of doxorubicin-induced cardiotoxicity. Overall, Fgf13 knockout attenuates doxorubicin-induced cardiomyocyte apoptosis and mitochondrial damage through the modulation of Parkin, indicating that FGF13 may serve as a promising therapeutic target for DOX-induced cardiotoxicity.
- 1 February 2026
- Published by China Science Publishing & Media Ltd. in Acta Biochimica et Biophysica Sinica
- Vol. 58 (7) , 1509-1518
Open AccessFibroblast growth factor 13 deficiency attenuates doxorubicin-induced cardiotoxicity by regulating Parkin-mediated myocardial injury
The clinical use of doxorubicin (DOX) as a chemotherapeutic agent is limited by its cardiotoxic effects. Fibroblast growth factor (FGF) isoform 13, a distinct type of FGF, has been increasingly recognized as an important regulator of cardiovascular disease. However, its role in doxorubicin-induced cardiotoxicity remains unknown. Therefore, the objective of this study is to investigate the role and mechanism of FGF13 in doxorubicin-induced cardiac injury. C57BL/6 mice are used to establish Dox-induced cardiotoxicity models. The results reveal that mouse weight, cardiomyocyte cross-sectional area, ejection fraction and fractional shortening are decreased in the DOX group. In contrast, Fgf13 deficiency mitigate doxorubicin-mediated cardiotoxicity, as indicated by increased mouse weight, cardiomyocyte cross-sectional area, ejection fraction and fractional shortening. Mechanistically, the protein expressions of bax and cleaved caspase 3 are elevated in the DOX-treated group, along with decreased JC-1 fluorescence intensity and bcl-2 expression, whereas Fgf13 knockout prevented these alterations. In addition, Parkin, but not p53, interact with FGF13 and is upregulated in response to Fgf13 deficiency in a mouse model of doxorubicin-induced cardiotoxicity. Overall, Fgf13 knockout attenuates doxorubicin-induced cardiomyocyte apoptosis and mitochondrial damage through the modulation of Parkin, indicating that FGF13 may serve as a promising therapeutic target for DOX-induced cardiotoxicity.
- Open Access
- 17 June 2024
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 16, 1390310
Single-cell sequencing of the substantia nigra reveals microglial activation in a model of MPTP
Background: N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin widely used to induce PD models, but the effect of MPTP on the cells and genes of PD has not been fully elucidated.Methods: Single-nucleus RNA sequencing was performed in the Substantia Nigra (SN) of MPTP mice. UMAP analysis was used for the dimensionality reduction visualization of the SN in the MPTP mice. Known marker genes highly expressed genes in each cluster were used to annotate most clusters. Specific Differentially Expressed Genes (DEGs) and PD risk genes analysis were used to find MPTP-associated cells. GO, KEGG, PPI network, GSEA and CellChat analysis were used to reveal cell type-specific functional alterations and disruption of cell-cell communication networks. Subset reconstruction and pseudotime analysis were used to reveal the activation status of the cells, and to find the transcription factors with trajectory characterized.Results: Initially, we observed specific DEGs and PD risk genes enrichment in microglia. Next, We obtained the functional phenotype changes in microglia and found that IGF, AGRN and PTN pathways were reduced in MPTP mice. Finally, we analyzed the activation state of microglia and revealed a pro-inflammatory trajectory characterized by transcription factors Nfe2l2 and Runx1.Conclusion: Our work revealed alterations in microglia function, signaling pathways and key genes in the SN of MPTP mice.
- 17 June 2024
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 16, 1390310
Open AccessSingle-cell sequencing of the substantia nigra reveals microglial activation in a model of MPTP
Background: N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin widely used to induce PD models, but the effect of MPTP on the cells and genes of PD has not been fully elucidated.Methods: Single-nucleus RNA sequencing was performed in the Substantia Nigra (SN) of MPTP mice. UMAP analysis was used for the dimensionality reduction visualization of the SN in the MPTP mice. Known marker genes highly expressed genes in each cluster were used to annotate most clusters. Specific Differentially Expressed Genes (DEGs) and PD risk genes analysis were used to find MPTP-associated cells. GO, KEGG, PPI network, GSEA and CellChat analysis were used to reveal cell type-specific functional alterations and disruption of cell-cell communication networks. Subset reconstruction and pseudotime analysis were used to reveal the activation status of the cells, and to find the transcription factors with trajectory characterized.Results: Initially, we observed specific DEGs and PD risk genes enrichment in microglia. Next, We obtained the functional phenotype changes in microglia and found that IGF, AGRN and PTN pathways were reduced in MPTP mice. Finally, we analyzed the activation state of microglia and revealed a pro-inflammatory trajectory characterized by transcription factors Nfe2l2 and Runx1.Conclusion: Our work revealed alterations in microglia function, signaling pathways and key genes in the SN of MPTP mice.
- 13 October 2023
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 20 (1) , 301-312
The Protective Effect of Chronic Intermittent Hypobaric Hypoxia on Preventing the Destruction of CD34+ Haematopoietic Stem Cells in Aplastic Anaemia by Modulating the Th1/Th2 Balance
Aplastic anaemia (AA) is a haematopoietic disorder caused by immune-mediated attack on haematopoietic stem cells (HSCs). Stem cell transplantation and immunosuppressive therapy remain the major treatment choice for AA patients but have limited benefits and undesired side effects. The aim of our study was to clarify the protective role of immunity of chronic intermittent hypobaric hypoxia (CIHH) and the underlying mechanism in AA. Our integrative analysis demonstrated that CIHH pre-treatment significantly improved haematopoiesis and survival in an AA rat model. We further confirmed that CIHH pre-treatment was closely associated with the Th1/Th2 balance and a large number of negative regulatory haematopoietic factors, such as TNF-α and IFN-γ, produced by hyperactive Th1 lymphocytes released in AA rats, which induced the death program in a large number of CD34+ HSCs by activating the Fas/FasL apoptosis pathway, while CIHH pre-treatment effectively downregulated the expression of TNF-α and IFN-γ, resulting in a reduction in Fas antigen expression in CD34+ HSCs. In summary, this study provides evidence that CIHH has good protective effect against AA by modulating immune balance in Th1/Th2 cells and may provide a new therapeutic strategy. Graphical Abstract
- 13 October 2023
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 20 (1) , 301-312
The Protective Effect of Chronic Intermittent Hypobaric Hypoxia on Preventing the Destruction of CD34+ Haematopoietic Stem Cells in Aplastic Anaemia by Modulating the Th1/Th2 Balance
Aplastic anaemia (AA) is a haematopoietic disorder caused by immune-mediated attack on haematopoietic stem cells (HSCs). Stem cell transplantation and immunosuppressive therapy remain the major treatment choice for AA patients but have limited benefits and undesired side effects. The aim of our study was to clarify the protective role of immunity of chronic intermittent hypobaric hypoxia (CIHH) and the underlying mechanism in AA. Our integrative analysis demonstrated that CIHH pre-treatment significantly improved haematopoiesis and survival in an AA rat model. We further confirmed that CIHH pre-treatment was closely associated with the Th1/Th2 balance and a large number of negative regulatory haematopoietic factors, such as TNF-α and IFN-γ, produced by hyperactive Th1 lymphocytes released in AA rats, which induced the death program in a large number of CD34+ HSCs by activating the Fas/FasL apoptosis pathway, while CIHH pre-treatment effectively downregulated the expression of TNF-α and IFN-γ, resulting in a reduction in Fas antigen expression in CD34+ HSCs. In summary, this study provides evidence that CIHH has good protective effect against AA by modulating immune balance in Th1/Th2 cells and may provide a new therapeutic strategy. Graphical Abstract
- 31 August 2022
- Published by Springer Nature in Investigational New Drugs
- Vol. 40 (6) , 1194-1205
Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2V617F and ASXL1 mutations
Summary The V617F mutation in Janus kinase 2 is considered one of the driver mutations leading to Philadelphia-negative myeloproliferative neoplasms (MPNs). Concurrent JAK2V617F and ASXL1 mutations accelerate the progression of myelofibrosis in patients with MPNs. Few therapies are currently available for patients with these two mutations. In our study, the combination of ruxolitinib with ABT-737 was evaluated in cells carrying JAK2V617F and ASXL1 double mutations. RNA sequencing indicated overactivated oxidative phosphorylation in JAK2V617F;Asxl1+/- cKit+ cells. The cell line model with JAK2V617F and ASXL1 double mutations (HEL-AKO cells) also exhibited dysregulated mitochondrial function with an increase in the reactive oxygen species levels and a decrease in the ATP levels. The colony growth inhibition rates of cells with JAK2V617F and ASXL1 double mutations were significantly lower than those of cells with only the JAK2V617F mutation. Combined treatment with ruxolitinib and ABT-737 promoted apoptosis and inhibited the proliferation of HEL-AKO cells. Cotreatment with the two drugs also inhibited the growth of bone marrow mononuclear cells isolated from patients with concurrent JAK2V617F and ASXL1 mutations. In conclusion, we provide preclinical evidence showing that the combination of ruxolitinib and ABT-737 is a promising therapeutic strategy for MPN patients with concurrent JAK2V617F and ASXL1 mutations.
- 31 August 2022
- Published by Springer Nature in Investigational New Drugs
- Vol. 40 (6) , 1194-1205
Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2V617F and ASXL1 mutations
Summary The V617F mutation in Janus kinase 2 is considered one of the driver mutations leading to Philadelphia-negative myeloproliferative neoplasms (MPNs). Concurrent JAK2V617F and ASXL1 mutations accelerate the progression of myelofibrosis in patients with MPNs. Few therapies are currently available for patients with these two mutations. In our study, the combination of ruxolitinib with ABT-737 was evaluated in cells carrying JAK2V617F and ASXL1 double mutations. RNA sequencing indicated overactivated oxidative phosphorylation in JAK2V617F;Asxl1+/- cKit+ cells. The cell line model with JAK2V617F and ASXL1 double mutations (HEL-AKO cells) also exhibited dysregulated mitochondrial function with an increase in the reactive oxygen species levels and a decrease in the ATP levels. The colony growth inhibition rates of cells with JAK2V617F and ASXL1 double mutations were significantly lower than those of cells with only the JAK2V617F mutation. Combined treatment with ruxolitinib and ABT-737 promoted apoptosis and inhibited the proliferation of HEL-AKO cells. Cotreatment with the two drugs also inhibited the growth of bone marrow mononuclear cells isolated from patients with concurrent JAK2V617F and ASXL1 mutations. In conclusion, we provide preclinical evidence showing that the combination of ruxolitinib and ABT-737 is a promising therapeutic strategy for MPN patients with concurrent JAK2V617F and ASXL1 mutations.